Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index; none of the 113 sources its claims cite is checked for support yet.

Molecular genetics and genomics of the ABO blood group system

Open access
Yamamoto, Fumiichiro · 2021 · Annals of Blood

Abstract

The A and B oligosaccharide antigens of the ABO blood group system are produced from the common precursor, H substance, by enzymatic reactions catalyzed by A and B glycosyltransferases (AT and BT) encoded by functional A and B alleles at the ABO genetic locus, respectively. In 1990, my research team cloned human A , B , and O allelic cDNAs. We then demonstrated this central dogma of ABO and opened a new era of molecular genetics. We identified four amino acid substitutions between AT and BT and inactivating mutations in the O alleles, clarifying the allelic basis of ABO. We became the first to achieve successful ABO genotyping, discriminating between AA and AO genotypes and between BB and BO , which was impossible using immunohematological/serological methods. We also identified mutations in several subgroup alleles and also in the cis-AB and B(A) alleles that specify the expression of the A and B antigens by single alleles. Later, other scientists interested in the ABO system characterized many additional ABO alleles. However, the situation has changed drastically in the last decade, due to rapid advances in next-generation sequencing (NGS) technology, which has allowed the sequencing of several thousand genes and even the entire genome in individual experiments. Genome sequencing has revealed not only the exome but also transcription/translation regulatory elements. RNA sequencing determines which genes and spliced transcripts are expressed. Because more than 500,000 human genomes have been sequenced and deposited in sequence databases, bioinformaticians can retrieve and analyze this data without generating it. Now, in this era of genomics, we can harness the vast sequence information to unravel the molecular mechanisms responsible for important biological phenomena associated with the ABO polymorphism. Two examples are presented in this review: the delineation of the ABO gene evolution in a variety of species and the association of single nucleotide variant (SNV) sites in the ABO gene with diseases and biological parameters through genome-wide association studies (GWAS).

Overview

CoChat Summary

TL;DR

This review traces the molecular genetics of the ABO blood group system from the 1990 cloning of A, B, and O cDNAs through functional characterization of alleles to genomic-era analyses of evolution and disease associations. It argues that ABO genotyping remains limited by uncharacterized variants and regulatory/other genetic factors, so ABO phenotyping continues to prevail over genotyping.

Key findings

  • Cloning of A, B, and O allelic cDNAs in 1990 showed that A and B transferases are 354 amino acids (353 in alternatively spliced transcripts) and differ by four amino acid substitutions at codons 176, 235, 266, and 268; most O alleles carry 261delG, while O03 carries G268R, and the first ABO genotyping discriminated AA vs AO and BB vs BO.
  • Functional assays in HeLa cells with AT/BT constructs and 14 AT-BT chimeras indicated that codons 266 and 268 are decisive for GalNAc/Gal sugar specificity, while codons 176 and 235 had no or slight effects; many ABO mutations still have undetermined functional significance.
  • In the genomic era, the ISBT table lists 207 ABO alleles (84 A, 49 B, 12 cis-AB/B(A), and 62 O); more than 500,000 human genomes have been sequenced, the ABO gene spans 24,818 bp, and non-synonymous SNVs occur at 549 of 1,065 coding nucleotides, prompting a proposed SNV-based allele nomenclature.
  • GWAS links ABO SNVs to diseases and biological parameters: VTE rs505922 P=1.5×10−14 and rs657152 P=2.2×10−13; group O has approximately 25% lower vWF/FVIII than group A; severe malaria OR=1.18, P=2×10−7; duodenal ulcer rs505922 OR=1.32, P=1.15×10−10; COVID-19 group A OR=1.45, P=1.48×10−4 and group O OR=0.65, P=1.06×10−5.

Methods

  • Narrative review article; no new primary experimental study is reported, and the text synthesizes the author’s prior work with published literature.
  • Data sources include published ABO molecular genetics studies, the ISBT Blood Group Allele Table, sequence databases such as Ensembl and GenBank, and GWAS results; the review also presents phylogenetic trees and an amino acid motif–A/B specificity code table.
  • Main analysis is qualitative synthesis and interpretation of sequence data, including functional assay results from prior publications and GWAS association statistics.

Limitations

  • The paper states that many relevant studies could not be cited due to space limitations; the functional significance of most SNVs in the ABO gene has not been determined; ABO phenotypes of most sequenced samples have not been characterized; and deduced ABO phenotypes from gene sequences may not be completely correct.
  • The paper notes remaining technical and economical limitations, that ABO effects on COVID-19 severity/mortality can be masked by stronger risk factors, that some malaria association studies did not show an association, and that older disease-association studies may have healthy-population selection bias.
  • Evident from the text: as a narrative review, it does not report systematic search or selection criteria, and several figures/tables are duplicated or modified from the author’s previous publications, so it is not an independent systematic synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.21037/aob-20-71

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 14 Not valid · 83 Not checked · 73 Own results and interpretations

71 more claims

Create a free account to see all 170 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 43
  • It may state two separate claims as one. 59
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 61 references

Research works printed but not linked: 33

  1. Yamamoto F, Marken J, Tsuji T, et al. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1->2Gal alpha 1->3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem 1990;265:1146-51. [Crossref] [PubMed]
  2. Yamamoto F, McNeill PD, Yamamoto M, et al. Molecular genetic analysis of the ABO blood group system: 4. Another type of O allele. Vox Sang 1993;64:175-8. [Crossref] [PubMed]
  3. Yamamoto F, McNeill PD, Hakomori S. Human histo-blood group A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992;187:366-74. [Crossref] [PubMed]
  4. Yamamoto F, McNeill PD, Yamamoto M, et al. Molecular genetic analysis of the ABO blood group system: 1. Weak subgroups: A3 and B3 alleles. Vox Sang 1993;64:116-9. [Crossref] [PubMed]
  5. Yamamoto F, McNeill PD, Yamamoto M, et al. Molecular genetic analysis of the ABO blood group system: 3. A(X) and B(A) alleles. Vox Sang 1993;64:171-4. [Crossref] [PubMed]
  6. Yamamoto F, McNeill PD, Kominato Y, et al. Molecular genetic analysis of the ABO blood group system: 2. -AB alleles. Vox Sang 1993;64:120-3. [Crossref] [PubMed]
  7. Yamamoto F, Cid E, Yamamoto M, et al. An integrative evolution theory of histo-blood group ABO and related genes. Sci Rep 2014;4:6601. [Crossref] [PubMed]
  8. Yamamoto M, Cid E, Yamamoto F. Molecular genetic basis of the human Forssman glycolipid antigen negativity. Sci Rep 2012;2:975. [Crossref] [PubMed]
  9. Svensson L, Hult AK, Stamps R, et al. Forssman expression on human erythrocytes: biochemical and genetic evidence of a new histo-blood group system. Blood 2013;121:1459-68. [Crossref] [PubMed]
  10. Yamamoto F. Evolutionary divergence of the ABO and GBGT1 genes specifying the ABO and FORS blood group systems through chromosomal rearrangements. Sci Rep 2017;7:9375. [Crossref] [PubMed]
  11. Mourant AE, Kope*c AC, Domaniewska-Sobczak K. Blood groups and diseases: a study of associations of diseases with blood groups and other polymorphisms. Oxford monographs on medical genetics. Oxford; New York: Oxford University Press, 1978.
  12. Smith NL, Chen MH, Dehghan A, et al. Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor. Circulation 2010;121:1382-92. [Crossref] [PubMed]
  13. Paré G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet 2008;4:e1000118 [Crossref] [PubMed]
  14. Melzer D, Perry JR, Hernandez D, et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008;4:e1000072 [Crossref] [PubMed]
  15. Paterson AD, Lopes-Virella MF, Waggott D, et al. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 2009;29:1958-67. [Crossref] [PubMed]
  16. Qi L, Cornelis MC, Kraft P, et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 2010;19:1856-62. [Crossref] [PubMed]
  17. Barbalic M, Dupuis J, Dehghan A, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 2010;19:1863-72. [Crossref] [PubMed]
  18. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006;46:1836-44. [Crossref] [PubMed]
  19. Cserti CM, Dzik WH. The ABO blood group system and malaria. Blood 2007;110:2250-8. [Crossref] [PubMed]
  20. Fry AE, Griffiths MJ, Auburn S, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe malaria. Hum Mol Genet 2008;17:567-76. [Crossref] [PubMed]
  21. Jallow M, Teo YY, Small KS, et al. Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet 2009;41:657-65. [Crossref] [PubMed]
  22. Band G, Le QS, Jostins L, et al. Imputation-based meta-analysis of severe malaria in three African populations. PLoS Genet 2013;9:e1003509 Erratum in: PLoS Genet 2013 Jun;9(6). doi:10.1371/annotation/adc2beaf-4bee-4e22-925b-6788d62fe029. Malaria Genomic Epidemiological Network [corrected to Malaria Genomic Epidemiology Network]. [Crossref] [PubMed] · DOI
  23. Malaria Genomic Epidemiology Network. A novel locus of resistance to severe malaria in a region of ancient balancing selection. Nature 2015;526:253-7. [Crossref] [PubMed]
  24. Malaria Genomic Epidemiology Network. Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania. Nat Commun 2019;10:5732. [Crossref] [PubMed]
  25. Barragan A, Kremsner PG, Wahlgren M, et al. Blood group A antigen is a coreceptor in rosetting. Infect Immun 2000;68:2971-5. [Crossref] [PubMed]
  26. Borén T, Falk P, Roth KA, et al. Attachment of to human gastric epithelium mediated by blood group antigens. Science 1993;262:1892-5. [Crossref] [PubMed]
  27. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. Clin Infect Dis 2021;73:328-31. [Crossref] [PubMed]
  28. Zeng X, Fan H, Lu D, et al. Association between ABO blood groups and clinical outcome of coronavirus disease 2019: Evidence from two cohorts. medRxiv Preprint 2020. doi: .
  29. Cheng Y, Cheng G, Chui CH, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005;293:1450-1. Erratum in: JAMA 2005 Aug 17;294(7):794. Cheng, Yufeng [corrected to Cheng, Yunfeng]. [PubMed]
  30. Arendrup M, Hansen JE, Clausen H, et al. Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors. AIDS 1991;5:441-4. [Crossref] [PubMed]
  31. Yamamoto F, Yamamoto M, Muñiz‐Diaz E. Blood group ABO polymorphism inhibits SARS‐CoV‐2 infection and affects COVID‐19 progression. Vox Sang 2021;116:15-7. [Crossref] [PubMed]
  32. Yamamoto F. ABO blood groups and SARS-CoV-2 infection. ResearchGate 2020. doi: . Available online: https://www.researchgate.net/publication/340209045_ABO_Blood_Groups_and_SARS-CoV-2_Infection
  33. Flegel WA. COVID-19: risk of infection is high, independently of ABO blood group. Haematologica 2020;105:2706-8. [Crossref] [PubMed] doi: 10.21037/aob-20-71 Cite this article as: Yamamoto F. Molecular genetics and genomics of the ABO blood group system. Ann Blood 2021;6:25.

Cited by

See all 30

Metadata

Authors
Yamamoto, F.
Affiliations
Josep Carreras Leukaemia Research Institute (ES)
Corresponding author
Yamamoto, Fumiichiro
Venue
Annals of Blood
Published
2021-09
Volume
6
Pages
25-25
ISSN
2521-361X (ISSN-L)
OpenAlex
W3147633926
Cited by
30
References
61
Citations by year
2026: 10 · 2025: 10 · 2024: 4 · 2023: 4 · 2022: 1 · 2021: 1
FWCI
1.49
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
Annals of Blood (publishedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
ABO blood group system, ABO gene, H antigen, ABO alleles, ABO genotyping, single nucleotide variants, genome-wide association study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular genetics and genomics of the ABO blood group system. https://app.cochat.ai/papers/10.21037/aob-20-71
The paper
Yamamoto, F. (2021). Molecular genetics and genomics of the ABO blood group system. Annals of Blood. https://doi.org/10.21037/aob-20-71

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.